Novartis-backed Inflazome raises $46M for their clinical challenge to prove NLRP3 is a great anti-inflammatory target
The big CANTOS study may not have produced the blockbuster approval that Novartis had been promising in cardio, but its success in the IL-1 beta …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
